Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02266823 · ClinicalTrials.gov registry record · NA

Diabetes CKD Lifestyle Technology Study

A NA study of Obesity and Diabetes, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
270
Enrollment target
1
Study location

NCT02266823: Completed NA study of Obesity and Diabetes, sponsored by NYU Langone Health.

NCT02266823 is a NA study of Obesity and Diabetes that has completed, run by NYU Langone Health. The registered enrollment target is 270 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02266823, a NA study of Obesity and Diabetes, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
270 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to pilot test an mHealth technology-supported behavioral intervention designed to engage patients with diabetes and concurrent chronic kidney disease (CKD) in multiple behaviors which aim to reduce CKD progression. Participants will be randomized to the 6-month lifestyle intervention or to a wait-list control. The lifestyle intervention will be modeled after that used in the Diabetes Prevention Program (DPP) and the counseling intervention will be based on SCT, which will be paired with mobile technology-based dietary and physical activity monitoring. The wait-list control will receive 6 months of standard medical care followed by a delayed, but less intensive, 6-month intervention.

Interventions

  • BEHAVIORAL Social Cognitive Theory

Study Locations (1)

New York

  • NYU Langone Medical Center - New York

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2015-10
Est. Completion 2019-11-08
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT02266823 record still lists

NCT02266823 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (67% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Social Cognitive Theory is the first listed.

NCT02266823 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02266823 about?

NCT02266823 is a clinical study titled "Diabetes CKD Lifestyle Technology Study". The purpose of this study is to pilot test an mHealth technology-supported behavioral intervention designed to engage patients with diabetes and concurrent chronic kidney disease (CKD) in multiple behaviors which aim to reduce CKD progression. Participants will be randomized to the 6-month lifestyle...

What is the current status of trial NCT02266823?

This trial is currently completed. It is a NA study. The enrollment target is 270 participants. The study started on 2015-10. Estimated completion is 2019-11-08.

What conditions does trial NCT02266823 study?

This clinical trial studies the following conditions: Obesity, Diabetes, Chronic Kidney Disease.

What interventions are being tested in trial NCT02266823?

The interventions under investigation include: Social Cognitive Theory (BEHAVIORAL).

Who is sponsoring clinical trial NCT02266823?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02266823 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02266823's enrollment target sits among peer trials

270 243rd of 1053 higher than 809 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02266823, the US trial registry maintained by the National Library of Medicine. NCT02266823 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.